PolTREG appoints Dan Shelly as Chief Business Development Officer

Prof. Shelly will help build partnerships that will allow the company to commercialise their pipeline of cell therapies

PolTREG S.A., has announced the appointment of Prof. Daniel Shelly as it’s new Chief Business Development officer. 

PolTREG are a clinical-stage biotechnology company developing cell therapies for a range of autoimmune diseases. 

Prof. Shelly has been brought in to help PolTREG build the strategic, commercial, research and pharmaceutical partnerships that will enable the company to successfully commercialise its strong pipeline of cell therapies for diseases such as Type-1 Diabetes (T1D), Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).

“I am very happy that Dan is joining us to help deliver the promise of Treg cell therapies for a wide range of autoimmune diseases. His arrival will enable us to continue to deliver the milestones that will bring our lead assets closer to market,” said Prof. Piotr Trzonkowski, CEO of PolTREG.

Dr Shelly is an veteran of the life science industry, with a deep understanding of biology and the Treg cell therapies that PolTREG is developing. 

He has a proven track record of closing business development deals for a wide range of biotech companies, including most recently several early-stage evaluation deals for Prescient Therapeutics Ltd., a clinical stage oncology company developing personalised medicine approaches to cancer, using CAR-T technologies. 

He was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He is an adjunct associate professor at the University of Cincinnati, where he teaches biologics discovery, pharmaco-economics and biotech business, publishes in scientific journals and is a frequently invited speaker and thought leader at international cell therapy conferences. 

Dr Shelly has a comprehensive understanding of the clinical development pathway, with direct experience of regulatory submissions, and is skilled in clinical asset valuation and due diligence.



You may also like